ATLASAurinia Pharmaceuticals (AUPH) earnings date: Nov 3, 2026
Aurinia Pharmaceuticals (AUPH) reports earnings for the quarter ended Sep 30, 2026 on Tue, Nov 3, 2026. Analysts expect EPS of $0.20.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on AUPH
| Last price | $16.65 (-3.3%) |
|---|---|
| Normal 1-day range (±1σ) | ±2.2% |
| Earnings beat history | Beat the EPS estimate in 5 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Aurinia Pharmaceuticals stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Aurinia Pharmaceuticals reports on Nov 3, 2026. One email the day before, with ATLAS’s read on Aurinia Pharmaceuticals. You can switch it off at any time.
Alert me before AUPH reportsFree to start. Creating an account takes under a minute.
AUPH earnings at a glance
| Next report (confirmed) | Tue, Nov 3, 2026 |
|---|---|
| Time | Not stated |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | $0.20 |
| Last report | Oct 30, 2026 |
| Beat rate (last 5 reports) | 5 of 5 (100%) |
| Average EPS surprise | +130.6% |
| Average move around a report | ±2.9% (last 5) |
| Sector | Healthcare · Biotechnology |
Aurinia Pharmaceuticals earnings history: last 6 reports
Aurinia Pharmaceuticals last reported on Oct 30, 2026: EPS of $0.23 against an estimate of $0.22.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Oct 30, 2026 | $0.22 | $0.23 | – | – | – |
| Aug 6, 2026 | $0.24 | $0.28 | +16.7% | Beat | +4.3% |
| May 7, 2026 | $0.20 | $0.25 | +25.0% | Beat | -6.3% |
| Feb 26, 2026 | $0.22 | $1.53 | +595.5% | Beat | -1.8% |
| Feb 12, 2026 | $1.03 | $1.07 | +3.9% | Beat | -1.9% |
| Jan 13, 2026 | $1.36 | $1.52 | +11.8% | Beat | -0.3% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for AUPH
See the fair value, the probability range and the earnings history of Aurinia Pharmaceuticals on its ATLAS page.
Aurinia Pharmaceuticals (AUPH) stock analysisPlans from €3.99 a month.
Aurinia Pharmaceuticals earnings: frequently asked questions
When does Aurinia Pharmaceuticals (AUPH) report earnings?
Aurinia Pharmaceuticals is scheduled to report on Tuesday, November 3, 2026 (the time of day has not been stated). ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for AUPH?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is $0.20 per share (USD). Estimates can change before the report.
How often does AUPH beat earnings estimates?
Of its last 5 reports with a recorded result, Aurinia Pharmaceuticals beat the EPS estimate 5 times; the average surprise was +130.6%. Past results do not predict the next one.
How much does AUPH move around earnings?
Over its last 5 reports the stock moved an average of 2.9% (absolute, from the close before the report day to the close after it), and finished higher 1 of 5 times.
Did Aurinia Pharmaceuticals beat earnings estimates last quarter?
Aurinia Pharmaceuticals last reported on Oct 30, 2026: EPS of $0.23 against an estimate of $0.22.
How much does AUPH usually move in a day?
On a normal trading day the ATLAS model puts AUPH’s one-day range at about ±2.2%, with a 50% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Tue, Nov 3, 2026
Educational information, not investment advice. Disclaimer